Skip to content

Psilocybin: all studies

Page 313 of 439: studies 3,121 to 3,130 of 4,389, newest first. Back to the psilocybin overview

Research

Clinical Characteristics of Emergency Visits Related to Recreational Psychedelic Use.

Community Mental Health Journal April 1, 2026 Kush V. Bhatt, Joseph Friedman, Lindsay L Benster et al.

Recreational psychedelic use is increasing, yet data on adverse events remains limited. This study characterized emergency department (ED) visits associated with recreational psychedelic use at UC San Diego Medical Center. We conducted a retrospective chart review of ED encounters (2010–2023). Cases were identified using ICD-10 hallucinogen-related codes and confirmed through manual review....

DOI: 10.1007/s10597-026-01620-x (opens in new tab) Full text (opens in new tab) Psychedelic Emergency department Hallucinogen Substance use

Specific and Multi‐Product Clade I and Clade IV Sesquiterpene Synthases Contribute to the Psilocybe cubensis Volatilome

ChemBioChem April 1, 2026 Sebastian Schober, Lisa Dorfmann, Karl Walther et al.

Apart from the psychedelic psilocybin, the metabolite spectrum of Psilocybe "magic mushrooms" comprises sesquiterpenes, a class of natural products known to exhibit receptor-modulating bioactivities. However, the composition of the sesquiterpene profile has largely remained an open question. Here, we report the characterization of five Psilocybe cubensis sesquiterpene synthases, both in vitro...

DOI: 10.1002/cbic.70318 (opens in new tab) Sesquiterpene Clade Mycelium Secondary metabolite +9

Complete biosynthesis of psychedelic tryptamines from three kingdoms in plants

Science Advances April 1, 2026 Paula Berman, Janka Höfer, Herschel Mehlman et al. 1 citation

-dimethyltryptamine (DMT) biosynthetic pathway in hallucinogenic plant species traditionally used in shamanic rituals for spiritual healing. Leveraging the similarities in their chemical structures, we reconstructed in one plant assay the full biosynthetic pathways of five renowned natural psychedelics; psilocin and psilocybin found in mushrooms, DMT from plants, and bufotenin and 5-methoxy-DMT...

An international mega-analysis of psychedelic drug effects on brain circuit function

Nature Medicine April 1, 2026 Manesh Girn, Manoj K. Doss, Leor Roseman et al. 8 citations

Psychedelic drugs are re-emerging as promising scientific and clinical tools. However, despite a rapidly expanding literature on their therapeutic value, the neural mechanisms underlying psychedelic effects remain unclear. Resting-state functional magnetic resonance imaging studies of acute psychedelic effects, conducted independently by several research groups, have so far yielded fragmented...

Mystical dynamics: renewal, luminous light, and ego disintegration as key features associated with mystical oneness—a psychometric analysis using the PES100 in controlled psychedelic studies

Religion, Brain & Behavior March 31, 2026 Kurt Stocker, Matthias Hartmann, Frederick S. Barrett et al.

Mystical dynamics—the notion that mystical oneness may unfold involving ego disintegration, renewal, and luminous light—has been discussed anecdotally by psychedelic researchers and therapists but has not yet been empirically examined in controlled settings. This study investigated the occurrence and dose-dependency of mystical dynamics in healthy participants after administration of...

DOI: 10.1080/2153599x.2026.2635353 (opens in new tab) Mysticism Psychometrics Key lock Psychometric testing +4

Three cases of wood-lover paralysis: clinical insights from Victoria, Australia.

Clinical Toxicology March 30, 2026 Annie Silvester, Sarah Hampton, Tom W May et al.

Introduction: Wood-lover paralysis is a rare complication of Psilocybe mushroom ingestion. The clinical spectrum is poorly characterized and published cases remain limited. Case presentations: We describe three patients who developed acute muscle weakness following ingestion of Psilocybe mushrooms in Victoria, Australia. Written informed consent was obtained from these patients for publication...

DOI: 10.1080/15563650.2026.2640196 (opens in new tab) Full text (opens in new tab) Humans Muscle weakness Mushroom poisoning Adult +7

Therapeutic Potential of Classical Psychedelics and NonHallucinogenic Psychoplastogens in Psychiatric Disorders

Psychiatry and Clinical Psychopharmacology March 30, 2026 Kenji Hashimoto, Feyza Arıcıoğlu, Mesut Çetin

Major depressive disorder remains a leading cause of disability worldwide, and current antidepressants are limited by delayed onset and incomplete response. Building on advances driven by ketamine research, renewed interest has focused on classical serotonergic psychedelics—particularly psilocybin, N,N-dimethyltryptamine (DMT), 5-methoxy-DMT, and lysergic acid diethylamide (LSD)—which, under...

Unlocking 'stuckness' and catalysing change: A qualitative study of clinician and service leader perspectives on psychedelic-assisted therapy for substance use and mental health problems.

Addiction March 30, 2026 Sarah J Catchlove, Katrin Oliver, Michael Savic et al.

Australia recently down-scheduled and authorised psychedelic-assisted therapies, including psilocybin, for certain mental health conditions. Evidence is emerging for potential application in substance use disorder treatment. However, regulatory developments have outpaced implementation readiness. While service leaders and clinicians are crucial to implementation, little research examines their...

DOI: 10.1111/add.70403 (opens in new tab) Full text (opens in new tab) Alcohol use disorders Health service design Implementation Integrated care +3

Mapping cognitive-behavioral approach in psychedelic-assisted treatment: a systematic review across phases with classic and non-classic psychedelics

European Archives of Psychiatry and Clinical Neuroscience March 28, 2026 Yves Martins Varela, Vagner Deuel O de Tavares, Luiza Macedo Delgado et al. 1 citation

The use of psychedelics in the treatment of psychopathologies has been expanding, highlighting Psychedelic-Assisted Psychotherapy (PAP) as a promising resource in mental health care. This systematic review investigates. This systematic review investigates whether and how cognitive-behavioral therapies are integrated with psychedelic substances—both classical and atypical—for the treatment of...

When I use a word . . . Terminology of hallucinogenic agents

BMJ March 27, 2026 J K Aronson

Many terms have been invented to describe different types of hallucinogenic drugs, sometimes based on an analogy with the symptoms of schizophrenia, such as “psychotomimetic” and “phrenotropic.” “Psychedelics” refers to drugs that act as agonists at serotonin 5-HT2A receptors in the brain; they include psilocybin, 5-methoxydimethyltryptamine, and N,N-dimethyltryptamine (tryptamine derivatives),...

DOI: 10.1136/bmj.s606 (opens in new tab) Full text (opens in new tab) Terminology Word group theory Hallucinogen Medline +4